Thursday, March 03, 2011

10 Popular Drugs Set to Lose Their Patents - TheStreet

According to IBISWorld, the top five best-sellers set to lose patent protection in each of the next two years are:

Patent Expiring in 2011ConditionCompany2010 U.S. Sales
Lipitor cholesterol Pfizer $5,329,000,000
Zyprexa antipsychotic Eli Lily $2,496,000,000
Levaquin antibiotics Johnson & Johnson $1,312,000,000
Concerta ADHD/ADD Johnson & Johnson $929,000,000
Protonix antacid Pfizer $690,000,000

Patent Expiring in 2012ConditionCompany2010 U.S. Sales
Plavixanti-plateletBristol-Myers Squibb /Sanofi-Aventis $6,154,000,000
Seroquel antipsychotic AstraZeneca $3,747,000,000
Singulair asthma Merck $3,224,000,000
Actos type 2 diabetes Takeda $3,351,000,000
Enbrel arthritis Amgen $3,304,000,000

Posted via email from Jack's posterous

No comments: